cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Terns Pharmaceuticals Inc
7 own
6 watching
Current Price
$5.17
$-0.14
(-2.64%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
670.47M
52-Week High
52-Week High
14.04400
52-Week Low
52-Week Low
4.38000
Average Volume
Average Volume
1.99M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization670.47M
icon52-Week High14.04400
icon52-Week Low4.38000
iconAverage Volume1.99M
iconDividend Yield--
iconP/E Ratio--
What does the Terns Pharmaceuticals Inc do?
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Read More
How much money does Terns Pharmaceuticals Inc make?
News & Events about Terns Pharmaceuticals Inc.
Zolmax
5 months ago
Terns Pharmaceuticals (NASDAQ:TERN Get Rating) had its target price increased by JPMorgan Chase & Co. from $6.00 to $9.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a neutral rating on the stock. Several other analysts have also recently commented on the stock. The ...
Ticker Report
5 months ago
Terns Pharmaceuticals (NASDAQ:TERN Get Rating) and Phibro Animal Health (NASDAQ:PAHC Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings...
Globe Newswire
6 months ago
Experienced Leader Brings Extensive Clinical Development and Medical Affairs Expertise in OncologyFOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...
Zolmax
7 months ago
UBS Group assumed coverage on shares of Terns Pharmaceuticals (NASDAQ:TERN Get Rating) in a research note published on Tuesday , Marketbeat.com reports. The brokerage issued a buy rating and a $19.00 target price on the stock. A number of other research analysts have also recently issued reports on ...
Globe Newswire
9 months ago
FOSTER CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (Terns or the Company) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic ...
Frequently Asked Questions
Frequently Asked Questions
What is Terns Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Terns Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Terns Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Terns Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Terns Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Terns Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Terns Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Terns Pharmaceuticals Inc?
plus_minus_icon
What percentage is Terns Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Terns Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.17
$-0.14
(-2.64%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00